Bacitracin (opthalmic)

Revision as of 06:22, 18 May 2015 by Gerald Chi. (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search

{{DrugProjectFormSinglePage |authorTag=Adeel Jamil, M.D. [1] |genericName=Bacitracin |aOrAn=a |drugClass=antibiotic |indicationType=treatment |indication=superficial ocular infections involving the conjunctiva and/or cornea caused by Bacitracin susceptible organisms. |adverseReactions=contact dermatitis |blackBoxWarningTitle=TITLE |blackBoxWarningBody=Condition Name: (Content) |fdaLIADAdult=* For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by Bacitracin susceptible organisms.

Dosing Information

  • The ointment should be applied directly into the conjunctival sac 1 to 3 times daily. In blepharitis all scales and crusts should be carefully removed and the ointment then spread uniformly over the lid margins. Patients should be instructed to take appropriate measures to avoid gross contamination of the ointment when applying the ointment directly to the infected eye.

|offLabelAdultGuideSupport=There is limited information regarding Off-Label Guideline-Supported Use of Bacitracin (opthalmic) in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding Off-Label Non–Guideline-Supported Use of Bacitracin (opthalmic) in adult patients. |offLabelPedGuideSupport=There is limited information regarding Off-Label Guideline-Supported Use of Bacitracin (opthalmic) in pediatric patients. |offLabelPedNoGuideSupport=There is limited information regarding Off-Label Non–Guideline-Supported Use of Bacitracin (opthalmic) in pediatric patients. |contraindications=* This product should not be used in patients with a history of hypersensitivity to Bacitracin. |warnings=====PRECAUTIONS:====

  • Bacitracin ophthalmic ointment should not be used in deep-seated ocular infections or in those that are likely to become systemic. The prolonged use of antibiotic containing preparations may result in overgrowth of nonsusceptible organisms particularly fungi. If new infections develop during treatment appropriate antibiotic or chemotherapy should be instituted.

|clinicalTrials=* Contact dermatitis |drugBox={{Drugbox2 | Verifiedfields = changed | verifiedrevid = 457285800 | IUPAC_name = (4R)-4-[(2S)-2-({2-[(1S)-1-amino-2-methylbutyl]- 4,5-dihydro-1,3-thiazol-5-yl}formamido)-4-methylpentanamido]-4-{[(1S)- 1-{[(3S,6R,9S,12R,15S,18R,21S)- 18-(3-aminopropyl)-12-benzyl-15-(butan-2-yl)-3-(carbamoylmethyl)- 6-(carboxymethyl)-9-(1H-imidazol-5-ylmethyl)-2,5,8,11,14,17,20- heptaoxo-1,4,7,10,13,16,19-heptaazacyclopentacosan-21-yl]carbamoyl}- 2-methylbutyl]carbamoyl}butanoic acid | image = Bacitracin A.png | image2 = Bacitracin ball-and-stick.png

| tradename = Baciim | Drugs.com = Monograph | pregnancy_AU = D | pregnancy_US = C | legal_AU = S4 | legal_US = Rx-only | routes_of_administration = Topical, intramuscular

| bioavailability = | protein_bound = | metabolism = | elimination_half-life =

| CASNo_Ref =  ☑Y | CAS_number_Ref =  ☑Y | CAS_number = 1405-87-4 | ATC_prefix = D06 | ATC_suffix = AX05 | ATC_supplemental = J01XX10 (WHO) R02AB04 (WHO) Template:ATCvet | PubChem = 439542 | DrugBank_Ref =  ☑Y

| DrugBank = DB00626

| ChemSpiderID_Ref =  ☑Y | ChemSpiderID = 10481985 | UNII_Ref =  ☑Y | UNII = 58H6RWO52I | KEGG_Ref =  ☒N | KEGG = D00128 | ChEMBL_Ref =  ☒N | ChEMBL = 1200558

| C=66 | H=103 | N=17 | O=16 | S=1 | molecular_weight = 1422.69 g/mol | smiles = O=C(O)C[C@H]3NC(=O)[C@H](Cc1cncn1)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC(=O)[C@H](CCCCNC(=O)[C@H](CC(N)=O)NC3=O)NC(=O)[C@@H](NC(=O)[C@@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)C4N=C(SC4)\nC(N)C(C)CC)C(C)CC)C(C)CC | InChI = 1/C66H103N17O16S/c1-9-35(6)52(69)66-81-48(32-100-66)63(97)76-43(26-34(4)5)59(93)74-42(22-23-50(85)86)58(92)83-53(36(7)10-2)64(98)75-40-20-15-16-25-71-55(89)46(29-49(68)84)78-62(96)47(30-51(87)88)79-61(95)45(28-39-31-70-33-72-39)77-60(94)44(27-38-18-13-12-14-19-38)80-65(99)54(37(8)11-3)82-57(91)41(21-17-24-67)73-56(40)90/h12-14,18-19,31,33-37,40-48,52-54H,9-11,15-17,20-30,32,67,69H2,1-8H3,(H2,68,84)(H,70,72)(H,71,89)(H,73,90)(H,74,93)(H,75,98)(H,76,97)(H,77,94)(H,78,96)(H,79,95)(H,80,99)(H,82,91)(H,83,92)(H,85,86)(H,87,88)/t35?,36?,37?,40-,41+,42+,43-,44+,45-,46-,47+,48?,52?,53-,54-/m0/s1 | InChIKey = CLKOFPXJLQSYAH-NVOBBBONBV | StdInChI_Ref =  ☑Y | StdInChI = 1S/C66H103N17O16S/c1-9-35(6)52(69)66-81-48(32-100-66)63(97)76-43(26-34(4)5)59(93)74-42(22-23-50(85)86)58(92)83-53(36(7)10-2)64(98)75-40-20-15-16-25-71-55(89)46(29-49(68)84)78-62(96)47(30-51(87)88)79-61(95)45(28-39-31-70-33-72-39)77-60(94)44(27-38-18-13-12-14-19-38)80-65(99)54(37(8)11-3)82-57(91)41(21-17-24-67)73-56(40)90/h12-14,18-19,31,33-37,40-48,52-54H,9-11,15-17,20-30,32,67,69H2,1-8H3,(H2,68,84)(H,70,72)(H,71,89)(H,73,90)(H,74,93)(H,75,98)(H,76,97)(H,77,94)(H,78,96)(H,79,95)(H,80,99)(H,82,91)(H,83,92)(H,85,86)(H,87,88)/t35?,36?,37?,40-,41+,42+,43-,44+,45-,46-,47+,48?,52?,53-,54-/m0/s1 | StdInChIKey_Ref =  ☑Y | StdInChIKey = CLKOFPXJLQSYAH-NVOBBBONSA-N }} |mechAction=* The antibiotic, Bacitracin, exerts a profound action against many gram-positive pathogens, including the common Streptococci and Staphylococci. It is also destructive for certain gram-negative organisms. It is ineffective against fungi. |howSupplied=NDC 48102-007-13 3 - 1 g sterile tamper evident tubes with ophthalmic tip.

NDC 48102-007-35 3.5 g (1/8 oz.) sterile tamper evident tubes with ophthalmic tip. |storage=* Store at 20°-25° C (68°-77° F) (See USP Controlled room temperature). |packLabel======PRINCIPAL DISPLAY PANEL - 3X1 G TUBES, CARTON LABEL=====

NDC 48102-007-13

Rx only

BACITRACIN OPHTHALMIC OINTMENT USP, 500 units/g STERILE

3 x 1 g tubes

Sterile Ophthalmic Ointment

Weighing 1 gram each

USUAL DOSAGE: Apply 1 to 3 times daily. See package insert for full prescribing information.

EACH GRAM CONTAINS: 500 units of Bacitracin per gram, White Petrolatum, Mineral Oil.

Keep tightly closed.

Store at 20°-25° C (68°-77° F) (See USP

Controlled room temperature).

Keep out of reach of children.

This image is provided by the National Library of Medicine.
PRINCIPAL DISPLAY PANEL - 1 G TUBE, IMMEDIATE CONTAINER LABEL

NDC 48102-007-11

STERILE

Rx only

BACITRACIN

OPHTHALMIC OINTMENT USP

500 units/g

NET WT 1 gm

This image is provided by the National Library of Medicine.
PRINCIPAL DISPLAY PANEL - 3.5 G TUBE, CARTON LABEL

NDC 48102-007-35

Rx only

BACITRACIN OPHTHALMIC OINTMENT USP STERILE

CONTAINS: 500 units of Bacitracin per gram, White Petrolatum, Mineral Oil.

NET WT 3.5 g (1/8 Oz)

USUAL DOSAGE: 3 applications daily. See insert for complete information.

KEEP TIGHTLY CLOSED STORE AT ROOM TEMPERATURE KEEP OUT OF REACH OF CHILDREN

See crimp of tube for Lot No. & Exp. Date

This image is provided by the National Library of Medicine.
PRINCIPAL DISPLAY PANEL - 3.5 G TUBE, IMMEDIATE CONTAINER LABEL

NDC 48102-007-35

BACITRACIN OPHTHALMIC OINTMENT USP STERILE

Rx only

USUAL DOSAGE: 3 applications daily. See insert for complete information.

WARNING: Keep out of reach of children.

See crimp for Lot No. and Exp. Date

CONTAINS: 500 units of Bacitracin per gram, White Petrolatum, Mineral Oil.

NET WT 3.5 g (1/8 Oz)

KEEP TIGHTLY CLOSED STORE AT ROOM TEMPERATURE

This image is provided by the National Library of Medicine.

|alcohol=Alcohol-Bacitracin (opthalmic) interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication. |brandNames=* Ocu-Tracin }}


Linked-in.jpg